Inhibition of HIV type 1 replication in CD4+ and CD14 + cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5AN6B

AIDS Research and Human Retroviruses

Volumn 23, Issue 1, 2007, Pages 123-134

  Dimitrova, Dessislava I ^a   Reichenbach, Nancy L ^a   Yang, Xiaowei ^a   Pfleiderer, Wolfgang ^b   Charubala, Ramamurthy ^b   Gaughan, John P ^a   Suh, Byungse ^a   Henderson, Earl E ^a   Suhadolnik, Robert J ^a   Rogers, Thomas J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; CASPASE 3; CD14 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DOUBLE STRANDED RNA; IMMUNOMODULATING AGENT; INTERFERON; N6 BENZYL 3' DEOXYADENYLYL (2'-5') 3' DEOXYADENYLYL (2'-5') 3' DEOXYADENYLYL (2'-2'') N9 [(2 '' HYDROXYETHOXY)METHYL]ADENINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; IMMUNOMODULATION; INNATE IMMUNITY; LIGAND BINDING; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; SERODIAGNOSIS; VIRUS INHIBITION; VIRUS REPLICATION;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD14; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MONOCYTES; OLIGORIBONUCLEOTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 4; VIRUS REPLICATION;

EID: 33846817309     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.0091     Document Type: Article

References (53)

1. Sen GC: Viruses and interferons. Annu Rev Microbiol 2001;55:255-281.
2. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
3. Goodbourn S, Didock L, and Randall RE: Interferons: Cell signaling, immune modulation, antiviral responses and virus counter-measures. J Gen Virol 2000;81:2341-2364.
4. Stark GR, Kerr IM, Williams BR, et al.: How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
5. Dong B and Silverman RH: 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 1995;270:4133-4137.
6. Castelli J, Wood KA, and Youle RJ: The 2-5A system in viral infection and apoptosis. Biomed Pharmacother 1998;52:386-390.
7. Soumelis V, Scott I, Gheyas F, et al.: Depletion of circulating natural type I interferon-producing cells in HIV infected AIDS patients. Blood 2001;8:906-912.
8. Feldman S, Stein D, Amrute S, et al.: Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol 2001;101:201-210.
9. Murray HW, Rubin BY, Masur H, and Roberts RB: Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:883-889.
10. Carter WA, Strayer DR, Brodsky I, et al.: Clinical immunological and virological effects of Ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1987;1:1286-1292.
11. Wu JM, Chiao JW, and Maayan S: Diagnostic value of the determination of an interferon-induced enzyme activity: Decreased 2′,5′- oligoadenylate dependent binding protein activity in AIDS patient lymphocytes. AIDS Res 1986;2:127-133.
12. Martinand C, Montavon C, Salehzada T, et al.: RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells. J Virol 1999;73:290-296.
13. 12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996;15:580-587.
14. Adelson ME, Martinand-Mari C, Iacono KT, et al.: Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Eur J Biochem 1999;264:806-815.
15. Iacono KT: Characterization of the human 2′,5′-oligoadenylate synthetase small isoform: Inhibition of HIV-1 replication through intracellular immunization and delineation of the ATP binding domain. Ph.D. dissertation. Temple University, 2002.
16. + hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny. J Interferon Cytokine Res 2005;25:345-360.
17. Sobol RW, Henderson EE, Kon N, et al.: Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/phosphodiester 2′,5′-oligoadenylate derivatives. J Biol Chem 1995;270:5963-5978.
18. Charubala R, Pfleiderer W, Suhadolnik RJ, et al.: Nucleotides. LXX. Inhibition of HIV-1 replication by chemically synthesized, nuclease-resistant, nontoxic (2′-5′)-oligoadenylate agonists. Helv Chim Acta 2002;85:2284-2299.
19. N6B. J Acquir Immune Defic Syndr 2002;30:9-20.
20. Su Y, Popik W, and Pitha PM: Inhibition of human immunodeficiency virus type 1 replication by a tat-activated, transduced interferon gene: Targeted expression to human immunodeficiency virus type 1-infected cells. J Virol 1995;69:110-121.
21. Cordelier P, Calarota SA, Pomerantz RJ, et al.: Inhibition of HIV-1 in the central nervous system by IFN-α2 delivered by an SV40 vector. J Interferon Cytokine Res 2003;23:477-488.
22. Dumoulin FL, Nischalke HD, Leifeld L, et al.: Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. J Immunol Methods 2000;241:109-119.
23. DeVita VT Jr, Hellman S, and Rosenberg SA, eds.: AIDS: Etiology, Diagnosis, Treatment and Prevention, 4th Ed. Lippincott-Raven, Philadelphia, 1997.
24. Chun T-W, Davey RT Jr, Ostrowski M, et al.: Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retro viral therapy. Nat Med 2000;6:757-761.
25. + cells against human immunodeficiency virus (HIV) infection after stable transfection with HIV LTR-2′,5′-oligoadenylate synthetase hybrid gene. FASEB J 1990;4:3124-3130.
26. Li X-L, Blackford JA, and Hassel BA: RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol 1998;72:2752-2759.
27. Berson JF, Long D, Doranz BJ, et al.: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996;70:6288-6295.
28. Feng Y, Broder CC, et al.: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
29. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
30. Choe H, Farzan M, Sun Y, et al.: Beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
31. Rusch L, Zhou A, and Silverman RH: Caspase-dependent apoptosis by 2′,5′-oligoadenylate activation of RNase L is enhanced by IFN-β. J Interferon Cytokine Res 2000;20:1091-1100.
32. Takeda K, Kaisho T, and Akira S: Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
33. Underhill DM and Ozinsky A: Toll-like receptors: Key mediators of microbe detection. Curr Opin Immunol 2002;14:103-110.
34. Lane HC, Davey V, Kovacs JA, et al.: Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990;112:805-811.
35. Shirazi Y and Pitha PM: Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 1992;66:1321-1328.
36. Skillman DR, Malone JL, Decker CD, et al.: Phase I trial of interferon alpha-n3 in early-stage human immunodeficiency virus type 1 disease: Evidence for drug safety, tolerance, and antiviral activity. J Infect Dis 1996;173:1107-1114.
37. Kovacs JA, Bechtel C, Davey RT Jr, et al.: Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: Results of a phase I/II trial. J Infect Dis 1996;173:840-848.
38. Baca-Regen L, Heinzinger N, Stevenson M, et al.: Alpha interferon-induced antiretroviral activities: Restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J Virol 1994;68:7559-7565.
39. Bednarik DP, Mosca JD, Raj NB, et al.: Inhibition of human immunodeficiency virus (HIV) replication by HIV-transactivated α2-interferon. Proc Natl Acad Sci USA 1989;86:4958-4962.
40. Ragheb JA, Couture L, Mullen C, et al.: Inhibition of human immunodeficiency virus type 1 by Tat/Rev regulated expression of cytosine deaminase, interferon α2, or diphtheria toxin compared with inhibition by transdominant Rev. Hum Gene Ther 1999;10:103-112.
41. Cordelier P, Calarota SA, and Strayer DS: Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle. J Hematother Stem Cell Res 2002;11:817-823.
42. Maitra RK and Silverman RH: Regulation of human immunodeficiency virus replication by 2′,5′-oligoadenylate-dependent RNase L. J Virol 1998;72:1146-1152.
43. Schmidt A, Zilberstein A, Shulman L, et al.: Interferon action: Isolation of nuclease F, a translation inhibitor activated by interferon-induced (2′-5′)oligo-isoadenylate. FEBS Lett 1978;95:257-264.
44. Schröder HC, Wenger R, Rottman M, et al.: Alteration of nuclear (2′,5′)oligoriboadenylate synthetase and nuclease activities preceding replication of human immunodeficiency virus in H9 cells. Biol Chem Hoppe Seyler 1988;369:985-995.
45. Schröder HC, Ugarkovic D, Wenger R, et al.: Binding of Tat protein to the TAR region of human immunodeficiency virus type 1 blocks TAR-mediated activation of (2′-5′)oligoadenylate synthetase. AIDS Res Hum Retroviruses 1990;6:659-672.
46. Sobol RW, Fisher WL, Reichenbach NL, et al.: HIV-1 reverse transcriptase: Inhibition by 2′,5′-oligoadenylates. Biochemistry 1993;32:12112-12118.
47. Müller WEG, Weiler BE, Charubala R, et al.: Cordycepin analogues of 2′,5′-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. Biochemistry 1991;30:2027-2033.
48. Jurk M, Heil F, Vollmer J, et al.: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
49. Hemmi H, Kaisho T, Takeuchi O, et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
50. Lee J, Chuang, T-H, Redecke V, et al.: Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;6646-6651.
51. Vaidya SA and Cheng G: Toll-like receptors and innate antiviral responses. Curr Opin Immunol 2003;15:402-407.
52. Doyle SE, Vaidya SA, O'Connell R, et al.: IRF3 mediates a TLR3/TLR4-speciic antiviral gene program. Immunity 2002;17:251-263.
53. Siren J, Pirhonen J, Julkunen I, et al.: IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28 and IL-29. J Immunol 2005;174:1932-1937.